Invention Grant
- Patent Title: ERBB4 activator screening assay
-
Application No.: US15984194Application Date: 2018-05-18
-
Publication No.: US10716830B2Publication Date: 2020-07-21
- Inventor: Mark R. Frey
- Applicant: Children's Hospital Los Angeles
- Applicant Address: US CA Los Angeles
- Assignee: Children's Hospital Los Angeles
- Current Assignee: Children's Hospital Los Angeles
- Current Assignee Address: US CA Los Angeles
- Agency: Nixon Peabody LLP
- Main IPC: G01N33/53
- IPC: G01N33/53 ; G01N33/563 ; G01N33/566 ; G01N33/68 ; G01N33/554 ; A61K38/18 ; G01N33/573
Abstract:
The invention provides methods, pharmaceutical compositions and kits for treating, inhibiting and/or reducing the severity of inflammatory bowel disease and necrotizing enterocolitis in a subject in need thereof by administering an effective amount of a composition comprising an activator of ErbB4.
Public/Granted literature
- US20180318391A1 USE OF NEUREGULIN-4 FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND NECROTIZING ENTEROCOLITIS Public/Granted day:2018-11-08
Information query
IPC分类:
